标记临床研究(XOMA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

XOMA 标记临床研究

休市中 06-05 16:00:00 EDT

42.09

-0.31

-0.73%

盘后42.09

+0.000.00%

16:15 EDT

最高42.30	最低42.03	成交量4.20万
今开42.30	昨收42.40	日振幅0.65%
总市值5.28亿	流通市值2.76亿	总股本1,254万
成交额176.83万	换手率0.64%	流通股本655.79万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"XOMA","market":"US","secType":"STK","nameCN":"标记临床研究","latestPrice":42.09,"timestamp":1780689600000,"preClose":42.4,"halted":0,"volume":41951,"hourTrading":{"tag":"盘后","latestPrice":42.09,"preClose":42.09,"latestTime":"16:15 EDT","volume":14,"amount":589.26,"timestamp":1780690521988,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.007311320754716868,"floatShares":6557900,"shares":12541030,"eps":1.569394,"marketStatus":"休市中","change":-0.31,"latestTime":"06-05 16:00:00 EDT","open":42.3,"high":42.3,"low":42.025,"amount":1768308,"amplitude":0.006486,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.569394,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1780905600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":517896000000,"exchange":"NASDAQ","adjPreClose":42.4,"preHourTrading":{"tag":"盘前","latestPrice":42.4,"preClose":42.4,"latestTime":"09:29 EDT","volume":7,"amount":296.8,"timestamp":1780666199916,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":42.09,"preClose":42.09,"latestTime":"16:15 EDT","volume":14,"amount":589.26,"timestamp":1780690521988,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.43853450324989196,"impliedVol":0.5258,"impliedVolPercentile":0.761},"requestUrl":"/m/hq/s/XOMA","defaultTab":"news","newsList":[{"id":"1182308829","title":"Ligand制药上调2026年营收指引至2.7-3.1亿美元 特许权使用费达2.25-2.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182308829","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182308829?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:09","pubTimestamp":1777288184,"startTime":"0","endTime":"0","summary":"Ligand制药公司近日宣布大幅上调2026年财务预期，将全年营收指引区间调整为2.7亿至3.1亿美元。其中特许权使用费收入预计将贡献2.25亿至2.5亿美元，展现出公司核心授权业务强劲的增长动能。\n这一乐观预测主要得益于其合作药企多项创新药物的商业化进展超预期。通过精准的授权合作模式，Ligand持续扩大其生物技术资产组合的价值变现能力。此次指引上调也反映出市场对其合作伙伴研发管线商业化前景的积极预期。\n作为专注医药特许权投资的企业，XOMA公司通过持有Ligand相关权益间接受益于这一利好消息。生物医药领域特许权经营模式的成熟发展，正为行业带来更可持续的增长路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGND","BK4007","BK4139","LU1559883803.SGD","IE0009354923.USD","XOMA","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106361138","title":"Ligand调升2026年调整后每股收益指引至8.50-9.50美元 预计2027年将带来1.50美元增值","url":"https://stock-news.laohu8.com/highlight/detail?id=1106361138","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106361138?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:03","pubTimestamp":1777287789,"startTime":"0","endTime":"0","summary":"生物制药企业Ligand Pharmaceuticals Inc.宣布上调2026财年业绩预期，将调整后每股收益预测区间从原先的8.00-9.00美元提升至8.50-9.50美元。此次修正主要基于公司核心特许经营权业务的强劲表现及里程碑款项的加速确认。值得注意的是，管理层同时发布2027年业绩展望，预期通过现有合作项目的推进与新授权协议的落地，调整后每股收益将获得1.50美元的额外增长。Ligand此次指引上调或将对拥有相关权益资产的投资组合产生积极影响，进一步巩固其在 royalty-based 商业模式中的战略地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","LGND","LU0566484027.USD","BK4139","BK4007","LU1559883803.SGD","XOMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147877354","title":"Ligand收购XOMA特许权 加速盈利增长并巩固其作为领先生物制药特许权整合商的地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1147877354","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147877354?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:02","pubTimestamp":1777287743,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals Inc.（纳斯达克：LGND）宣布将收购XOMA Corp（纳斯达克：XOMA）的特许权资产，这一战略举措预计将显著推动其盈利增长。通过此次收购，Ligand将进一步巩固其在生物制药领域作为领先特许权整合商的地位。\n该交易将增强Ligand的特许权组合，为其带来更稳定的现金流和多元化的收入来源。作为生物制药特许权领域的重要参与者，Ligand通过此次收购展示了其在行业内的战略布局能力。市场观察人士认为，这一动作将提升Ligand在资本市场的吸引力，并为长期价值创造奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE0009354923.USD","BK4007","XOMA","LGND","LU1559883803.SGD","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617597360","title":"标记临床研究盘中异动 急速拉升5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617597360","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617597360?lang=zh_cn&edition=full","pubTime":"2026-03-05 01:18","pubTimestamp":1772644727,"startTime":"0","endTime":"0","summary":"北京时间2026年03月05日01时18分，标记临床研究股票出现波动，股价大幅拉升5.17%。截至发稿，该股报26.86美元/股，成交量2.0771万股，换手率0.17%，振幅7.22%。标记临床研究股票所在的生物技术行业中，整体涨幅为0.85%。标记临床研究公司简介：XOMA Royalty Corp是一家生物技术专利使用费聚合公司，在帮助生物技术公司实现改善人类健康的目标方面发挥着重要作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030501184797a810e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030501184797a810e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XOMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170050568","title":"XOMA公司预计2025财年特许权使用费与里程碑付款现金收入将达4900万至5000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170050568","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170050568?lang=zh_cn&edition=full","pubTime":"2026-03-02 19:25","pubTimestamp":1772450722,"startTime":"0","endTime":"0","summary":"XOMA公司发布最新财务展望，预计在2025财年通过特许权使用费和里程碑付款获得的现金收入将达到约4900万至5000万美元区间。这一预测反映了公司现有合作项目逐步进入商业化阶段所带来的收益增长。\n作为专注于生物技术领域投资的专业机构，XOMA通过持有创新疗法项目的特许权权益实现长期价值。此次公布的现金收入预期，凸显了其资产组合中多个项目持续产生的现金流潜力。该数字较往年同期呈现稳健增长态势，为公司后续战略布局提供了资金保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XOMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609548701","title":"标记临床研究盘中异动 急速上涨5.30%报26.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609548701","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609548701?lang=zh_cn&edition=full","pubTime":"2026-02-07 01:03","pubTimestamp":1770397388,"startTime":"0","endTime":"0","summary":"北京时间2026年02月07日01时03分，标记临床研究股票出现异动，股价急速上涨5.30%。截至发稿，该股报26.24美元/股，成交量4.2923万股，换手率0.35%，振幅3.13%。标记临床研究股票所在的生物技术行业中，整体涨幅为1.41%。XOMA获得了与已授权给制药或生物技术公司的商业化前候选治疗相关的潜在未来经济效益。XOMA获得未来的经济权利，卖方获得非稀释性、无追索权的资金，可用于推进其内部候选药物或用于一般公司目的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020701030895403354&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020701030895403354&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XOMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603752097","title":"标记临床研究盘中异动 急速下跌5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603752097","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603752097?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:32","pubTimestamp":1768228372,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时32分，标记临床研究股票出现异动，股价大幅下跌5.44%。截至发稿，该股报28.23美元/股，成交量2.9927万股，换手率0.24%，振幅3.64%。标记临床研究股票所在的生物技术行业中，整体跌幅为0.81%。标记临床研究公司简介：XOMA Royalty Corp是一家生物技术专利使用费聚合公司，在帮助生物技术公司实现改善人类健康的目标方面发挥着重要作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223252953c6c83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223252953c6c83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XOMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184168241","title":"标记临床研究：有权获得武田外部化资产组合中九项开发阶段资产相关付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1184168241","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184168241?lang=zh_cn&edition=full","pubTime":"2025-12-30 20:33","pubTimestamp":1767097992,"startTime":"0","endTime":"0","summary":"标记临床研究公司宣布，其已获得与武田制药外部化资产组合内九项处于开发阶段的资产相关的付款权利。这一安排进一步巩固了标记临床研究在生物医药特许权投资领域的地位，同时凸显了武田对其研发管线进行战略优化的举措。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XOMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133750981","title":"XOMA与武田就Mezagitamab达成战略版税共享协议并修订现有条款","url":"https://stock-news.laohu8.com/highlight/detail?id=1133750981","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133750981?lang=zh_cn&edition=full","pubTime":"2025-12-30 20:30","pubTimestamp":1767097821,"startTime":"0","endTime":"0","summary":"XOMA公司（XOMA Corp）与武田制药（Takeda）近日宣布，双方已就实验性药物Mezagitamab达成一项战略性的版税共享交易。此次合作不仅涉及对现有协议的修订，更通过创新性的版税分配机制深化了双方在药物开发领域的伙伴关系。该举措有望为两家企业带来更灵活的利益共享模式，同时加速Mezagitamab的临床推进进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XOMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518984274","title":"标记临床研究盘中异动 早盘股价大跌7.38%报20.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518984274","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518984274?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:26","pubTimestamp":1741616797,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时26分，标记临床研究股票出现异动，股价大幅跳水7.38%。截至发稿，该股报20.21美元/股，成交量1.4508万股，换手率0.12%，振幅8.57%。最近的财报数据显示，该股实现营业收入7.20百万美元，净利润-17.24百万美元，每股收益-1.59美元，毛利7.19百万美元，市盈率-6.83倍。标记临床研究股票所在的生物技术行业中，整体涨幅为0.39%。XOMA获得了与已授权给制药或生物技术公司的商业化前候选治疗相关的潜在未来经济效益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310222637abf31101&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310222637abf31101&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XOMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516512316","title":"标记临床研究盘中异动 快速下挫5.73%报21.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516512316","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516512316?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:05","pubTimestamp":1741025132,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时05分，标记临床研究股票出现波动，股价大幅下跌5.73%。截至发稿，该股报21.40美元/股，成交量2.8404万股，换手率0.24%，振幅4.98%。标记临床研究股票所在的生物技术行业中，整体涨幅为0.30%。XOMA获得了与已授权给制药或生物技术公司的商业化前候选治疗相关的潜在未来经济效益。当XOMA获得未来的经济权利时，卖方将获得非稀释性、无追索权的资金，这些资金可用于推进其内部候选药物或用于一般公司用途。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040205339637de0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040205339637de0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XOMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512162677","title":"标记临床研究盘中异动 大幅下跌5.08%报25.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512162677","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512162677?lang=zh_cn&edition=full","pubTime":"2025-02-19 00:11","pubTimestamp":1739895091,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日00时11分，标记临床研究股票出现波动，股价大幅下跌5.08%。截至发稿，该股报25.40美元/股，成交量6904股，换手率0.06%，振幅2.77%。标记临床研究股票所在的生物技术行业中，整体涨幅为0.92%。XOMA获得了与已授权给制药或生物技术公司的商业化前候选治疗相关的潜在未来经济效益。当XOMA获得未来的经济权利时，卖方将获得非稀释性、无追索权的资金，这些资金可用于推进其内部候选药物或用于一般公司用途。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219001131988a0f02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219001131988a0f02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XOMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508125463","title":"标记临床研究盘中异动 大幅跳水5.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508125463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508125463?lang=zh_cn&edition=full","pubTime":"2025-02-04 01:09","pubTimestamp":1738602541,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日01时09分，标记临床研究股票出现异动，股价急速下跌5.67%。截至发稿，该股报25.10美元/股，成交量1.4863万股，换手率0.13%，振幅3.14%。标记临床研究股票所在的生物技术行业中，整体跌幅为0.68%。标记临床研究公司简介：XOMA Royalty Corp是一家生物技术专利使用费聚合公司，在帮助生物技术公司实现改善人类健康的目标方面发挥着重要作用。XOMA获得了与已授权给制药或生物技术公司的商业化前候选治疗相关的潜在未来经济效益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204010901abc127a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204010901abc127a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XOMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508114544","title":"HC Wainwright & Co.：维持XOMA Royalty(XOMA.US)评级，由买入调整至买入评级, 目标价由123.00美元调整至104.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508114544","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508114544?lang=zh_cn&edition=full","pubTime":"2025-02-03 19:31","pubTimestamp":1738582298,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持XOMA Royalty(XOMA.US)评级，由买入调整至买入评级, 目标价由123.00美元调整至104.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/03193147940539.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["XOMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503562238","title":"标记临床研究盘中异动 快速上涨5.77%报28.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503562238","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503562238?lang=zh_cn&edition=full","pubTime":"2025-01-16 00:37","pubTimestamp":1736959070,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日00时37分，标记临床研究股票出现波动，股价急速上涨5.77%。截至发稿，该股报28.25美元/股，成交量1.2102万股，换手率0.10%，振幅2.94%。标记临床研究股票所在的生物技术行业中，整体涨幅为0.92%。XOMA获得了与已授权给制药或生物技术公司的商业化前候选治疗相关的潜在未来经济效益。当XOMA获得未来的经济权利时，卖方将获得非稀释性、无追索权的资金，这些资金可用于推进其内部候选药物或用于一般公司用途。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116003750abac0fdc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116003750abac0fdc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XOMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503503826","title":"标记临床研究盘中异动 快速拉升5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503503826","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503503826?lang=zh_cn&edition=full","pubTime":"2025-01-14 22:42","pubTimestamp":1736865721,"startTime":"0","endTime":"0","summary":"北京时间2025年01月14日22时42分，标记临床研究股票出现波动，股价急速上涨5.20%。截至发稿，该股报26.72美元/股，成交量514股，换手率0.00%，振幅0.00%。标记临床研究股票所在的生物技术行业中，整体跌幅为0.44%。标记临床研究公司简介：XOMA Royalty Corp是一家生物技术专利使用费聚合公司，在帮助生物技术公司实现改善人类健康的目标方面发挥着重要作用。XOMA获得了与已授权给制药或生物技术公司的商业化前候选治疗相关的潜在未来经济效益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114224201abaaaf60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250114224201abaaaf60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XOMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502928899","title":"标记临床研究盘中异动 早盘股价大跌5.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502928899","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502928899?lang=zh_cn&edition=full","pubTime":"2025-01-11 00:15","pubTimestamp":1736525735,"startTime":"0","endTime":"0","summary":"北京时间2025年01月11日00时15分，标记临床研究股票出现波动，股价大幅下挫5.98%。截至发稿，该股报24.20美元/股，成交量6455股，换手率0.05%，振幅1.13%。标记临床研究股票所在的生物技术行业中，整体跌幅为1.63%。标记临床研究公司简介：XOMA Royalty Corp是一家生物技术专利使用费聚合公司，在帮助生物技术公司实现改善人类健康的目标方面发挥着重要作用。XOMA获得了与已授权给制药或生物技术公司的商业化前候选治疗相关的潜在未来经济效益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011100153595ff83c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011100153595ff83c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XOMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2493764004","title":"标记临床研究盘中异动 下午盘急速拉升5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2493764004","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493764004?lang=zh_cn&edition=full","pubTime":"2024-12-21 02:12","pubTimestamp":1734718320,"startTime":"0","endTime":"0","summary":"北京时间2024年12月21日02时12分，标记临床研究股票出现异动，股价快速上涨5.14%。截至发稿，该股报26.40美元/股，成交量2.4419万股，换手率0.21%，振幅7.21%。标记临床研究股票所在的生物技术行业中，整体涨幅为0.72%。标记临床研究公司简介：XOMA Royalty Corp是一家生物技术专利使用费聚合公司，在帮助生物技术公司实现改善人类健康的目标方面发挥着重要作用。XOMA获得了与已授权给制药或生物技术公司的商业化前候选治疗相关的潜在未来经济效益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/us/2024-12-21/doc-ineacxhi5519536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XOMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492915551","title":"标记临床研究盘中异动 股价大跌5.30%报25.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492915551","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492915551?lang=zh_cn&edition=full","pubTime":"2024-12-19 04:07","pubTimestamp":1734552462,"startTime":"0","endTime":"0","summary":"北京时间2024年12月19日04时07分，标记临床研究股票出现波动，股价急速下跌5.30%。截至发稿，该股报25.70美元/股，成交量2.928万股，换手率0.25%，振幅5.93%。标记临床研究股票所在的生物技术行业中，整体跌幅为1.97%。XOMA获得了与已授权给制药或生物技术公司的商业化前候选治疗相关的潜在未来经济效益。当XOMA获得未来的经济权利时，卖方将获得非稀释性、无追索权的资金，这些资金可用于推进其内部候选药物或用于一般公司用途。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219040742ab82916c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219040742ab82916c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XOMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2491515353","title":"标记临床研究盘中异动 快速下跌5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491515353","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491515353?lang=zh_cn&edition=full","pubTime":"2024-12-13 02:57","pubTimestamp":1734029877,"startTime":"0","endTime":"0","summary":"北京时间2024年12月13日02时57分，标记临床研究股票出现异动，股价快速下挫5.45%。截至发稿，该股报27.75美元/股，成交量9714股，换手率0.08%，振幅4.50%。标记临床研究股票所在的生物技术行业中，整体跌幅为1.09%。标记临床研究公司简介：XOMA Royalty Corp是一家生物技术专利使用费聚合公司，在帮助生物技术公司实现改善人类健康的目标方面发挥着重要作用。XOMA获得了与已授权给制药或生物技术公司的商业化前候选治疗相关的潜在未来经济效益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213025757a1e9c648&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241213025757a1e9c648&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","XOMA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xoma.com","stockEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":0.0118},{"period":"3month","weight":0.6201},{"period":"6month","weight":0.4072},{"period":"1year","weight":0.6836},{"period":"ytd","weight":0.5829}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"XOMA Royalty Corporation于1981年在特拉华州注册成立并于2025年5月在内华达州重新注册成立。该公司是一家生物技术版税聚合商，在帮助生物技术公司实现改善人类健康的目标方面发挥着独特的作用。该公司获得了与已授权给制药或生物技术公司的预商业化和商业化治疗候选药物相关的潜在未来经济性。","yearOnYearQuotes":[{"month":1,"riseRate":0.575,"avgChangeRate":0.053986},{"month":2,"riseRate":0.475,"avgChangeRate":-0.011582},{"month":3,"riseRate":0.4,"avgChangeRate":0.005611},{"month":4,"riseRate":0.5,"avgChangeRate":-0.003258},{"month":5,"riseRate":0.55,"avgChangeRate":0.056505},{"month":6,"riseRate":0.45,"avgChangeRate":0.004124},{"month":7,"riseRate":0.45,"avgChangeRate":-0.005749},{"month":8,"riseRate":0.475,"avgChangeRate":0.052237},{"month":9,"riseRate":0.35,"avgChangeRate":-0.010798},{"month":10,"riseRate":0.4,"avgChangeRate":-0.033618},{"month":11,"riseRate":0.525,"avgChangeRate":0.022745},{"month":12,"riseRate":0.45,"avgChangeRate":0.042998}],"exchange":"NASDAQ","name":"标记临床研究","nameEN":"XOMA Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"标记临床研究(XOMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供标记临床研究(XOMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"标记临床研究,XOMA,标记临床研究股票,标记临床研究股票老虎,标记临床研究股票老虎国际,标记临床研究行情,标记临床研究股票行情,标记临床研究股价,标记临床研究股市,标记临床研究股票价格,标记临床研究股票交易,标记临床研究股票购买,标记临床研究股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"标记临床研究(XOMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供标记临床研究(XOMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}